The First Weekly Oral Treatment Plan! Dr. Amy Colson Shares Phase 2 Study Results of Islatravir Combined with Lenacapavir at the CROI Conference

The First Weekly Oral Treatment Plan! Dr. Amy Colson Shares Phase 2 Study Results of Islatravir Combined with Lenacapavir at the CROI Conference

2024.04.13
Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) currently under development, while lenacapavir belongs to a new class of capsid inhibitors, both featuring long half-lives and highlighted as part of long-acting treatment strategies. Previously, the clinical development of islatravir was temporarily halted due to adverse events involving reductions in CD4 cells and lymphocytes. However, after dose adjustments, the combined use with lenacapavir in a phase 2 trial revealed positive outcomes at the recent CROI conference, promising the first all-oral weekly treatment plan for HIV patients. Infectious Disease Frontier interviewed Dr. Amy Colson, the study's Principal Investigator and Director of Research at the Community Resource Initiative, at the event.
Dr.Taisheng Li’s Team Presents the “Chinese Solution” for HIV Immune Reconstitution Deficiency at CROI 2024

Dr.Taisheng Li’s Team Presents the “Chinese Solution” for HIV Immune Reconstitution Deficiency at CROI 2024

2024.03.29
At the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held from March 3 to 6 in Denver, Colorado, USA, a study by Dr. Taisheng Li's team from the Peking Union Medical College Hospital was selected for a poster presentation and discussed at the fifth session. This conference, which started in 1993, has become one of the most influential meetings in the field of AIDS, attracting experts from around the world to share their latest research findings. The study presented by Dr. Li's team showcased a "Chinese solution" for addressing immune reconstitution deficiencies in HIV-infected individuals to the global academic community.
Dr. Shuihua Lu: First RCT Study Reported on a Novel Vaccine for Preventing Tuberculosis Relapse丨CROI Commentary

Dr. Shuihua Lu: First RCT Study Reported on a Novel Vaccine for Preventing Tuberculosis Relapse丨CROI Commentary

2024.03.29
Patients who have successfully completed tuberculosis treatment still face a high risk of relapse, making the development of vaccines to prevent recurrent pulmonary tuberculosis an important direction in TB prevention efforts. At the recently concluded 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), a study presented as a late-breaking abstract (Abstract Number: 210) revealed that the novel tuberculosis vaccine H56:IC31, while not reducing the rate of TB relapse, enhanced both humoral and cellular immune responses in recipients. This marks the first clinical multicenter, randomized controlled trial (RCT) reported on the use of a TB vaccine for the prevention of relapse. The Infectious Disease Frontier has invited Dr. Shuihua Lu and his team from The Third People's Hospital of Shenzhen to introduce and comment on this study as follows.
Dr. Shuihua Lu: Trends in PAN-TB Treatment and Mid-term Report Review on QDB Study丨CROI Commentary

Dr. Shuihua Lu: Trends in PAN-TB Treatment and Mid-term Report Review on QDB Study丨CROI Commentary

2024.03.29
In recent years, the concept of PAN-TB treatment, representing a comprehensive approach to tuberculosis (TB) therapy, has seen numerous developmental breakthroughs. This universal treatment method is applicable to all types of TB patients and is not limited by the resistance of traditional anti-tuberculosis drugs (i.e., there's no need to test for drug resistance), offering advantages such as simplified treatment and shortened course duration. At the recently concluded 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), a Phase 2b/c study (Abstract No: 163) presented in the form of a late-breaking abstract was selected for oral presentation. This study explored the efficacy and safety of a 4-month regimen of Quabodepistat, Delamanid, and Bedaquiline in treating pulmonary TB. Infectious Disease Frontier has invited Dr.
Dr. Hui Wang: Long-acting Cabotegravir Maintains High Efficacy in Preventing HIV Among Populations with High Incidence of Bacterial STIs丨CROI Commentary

Dr. Hui Wang: Long-acting Cabotegravir Maintains High Efficacy in Preventing HIV Among Populations with High Incidence of Bacterial STIs丨CROI Commentary

2024.03.28
The association between sexually transmitted infections (STIs) and HIV infection has always been a focal point in the medical community. With the promotion of pre-exposure prophylaxis (PrEP) strategies to prevent HIV infection, the impact of STIs on the effectiveness of PrEP has become an urgent issue to address. At the recently concluded Conference on Retroviruses and Opportunistic Infections (CROI 2024), researchers presented an oral abstract (Abstract 131) that explored the relationship between STI status and the effectiveness of two PrEP regimens (CAB-LA and daily oral TDF/FTC). Infectious Disease Frontier invited Dr. Hui Wang from The Third People's Hospital of Shenzhen to provide an in-depth commentary on this study.
Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature

Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature

2024.03.20
In December 2023, professor Erlie Jiang and  team from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published an influential study in Frontiers in Immunology, detailing the challenges of managing refractory cytomegalovirus (CMV) infections in Chinese patients after allogeneic hematopoietic cell transplantation (allo-HCT). With a focus on China's unique position in the global context of allo-HCT and the specific difficulties faced by patients with haploidentical donors, this review underscores the urgent need for standardized care protocols. Jiang's work, through its comprehensive analysis of existing literature, significantly advances our understanding of CMV management post-transplant, aiming to improve patient outcomes and establish effective treatment guidelines. This study marks a critical step forward in optimizing post-transplant care to enhance patient survival and quality of life amidst CMV infection challenges.

Website Disclaimer

2024.03.02
Content marked as original on the "Infectious Disease Frontier" platform holds copyright under Infectious Disease Frontier. While we encourage sharing and reproduction of our content, it must be done with prior written consent from Infectious Disease Frontier. Unauthorized use is strictly prohibited, and legal action may be taken against infringement.
Advancements in Predicting Patient Outcomes: A Multidimensional Approach to COVID-19 with the Omicron Variant

Advancements in Predicting Patient Outcomes: A Multidimensional Approach to COVID-19 with the Omicron Variant

2024.02.20
The COVID-19 pandemic, heightened by the emergence of the Omicron variant, has presented substantial challenges in managing patient conditions and predicting outcomes. Researchers at Peking Union Medical College Hospital sought to address this by developing a dynamic prediction model utilizing machine learning techniques. This study aimed to accurately forecast the deterioration or recovery of hospitalized COVID-19 patients, incorporating daily multidimensional data from 995 patients. Employing an ensemble machine learning approach, the researchers utilized the XGBoost algorithm. The resulting models exhibited promising discrimination capabilities, offering a valuable tool for clinicians to assess the likelihood of condition changes in the medium term.